Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof

Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigenbinding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors an...

Full description

Saved in:
Bibliographic Details
Main Authors Fisher, Jamie, Gaudet, Francois, Strake, Brandy, Cardoso, Rosa Maria Fernandes, Pizutti, Darlene, Rich, Bradley J, Salvati, Mark E, Dinh, Thai, Attar, Ricardo Marcos, Nemeth, Jennifer F, Nishioka Jr., Walter K
Format Patent
LanguageEnglish
Published 17.05.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigenbinding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor IL1RAP-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with IL1RAP-expressing cancer and thus may be amenable to treatment with an IL1RAP-specific anti-cancer therapeutic, such as the multispecific antibodies against IL1RAP and CD3 described herein.
Bibliography:Application Number: AU20160350705